201 related articles for article (PubMed ID: 21433156)
1. 31P MRSI and 1H MRS at 7 T: initial results in human breast cancer.
Klomp DW; van de Bank BL; Raaijmakers A; Korteweg MA; Possanzini C; Boer VO; van de Berg CA; van de Bosch MA; Luijten PR
NMR Biomed; 2011 Dec; 24(10):1337-42. PubMed ID: 21433156
[TBL] [Abstract][Full Text] [Related]
2. 31P magnetic resonance spectroscopic imaging with polarisation transfer of phosphomono- and diesters at 3 T in the human brain: relation with age and spatial differences.
Wijnen JP; Scheenen TW; Klomp DW; Heerschap A
NMR Biomed; 2010 Oct; 23(8):968-76. PubMed ID: 20669234
[TBL] [Abstract][Full Text] [Related]
3. Investigation of breast cancer using two-dimensional MRS.
Thomas MA; Lipnick S; Velan SS; Liu X; Banakar S; Binesh N; Ramadan S; Ambrosio A; Raylman RR; Sayre J; DeBruhl N; Bassett L
NMR Biomed; 2009 Jan; 22(1):77-91. PubMed ID: 19086016
[TBL] [Abstract][Full Text] [Related]
4. Combined DCE-MRI and single-voxel 2D MRS for differentiation between benign and malignant breast lesions.
Lipnick S; Liu X; Sayre J; Bassett LW; Debruhl N; Thomas MA
NMR Biomed; 2010 Oct; 23(8):922-30. PubMed ID: 20878970
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 31P high-resolution magic angle spinning of intact tissue samples.
Payne GS; Troy H; Vaidya SJ; Griffiths JR; Leach MO; Chung YL
NMR Biomed; 2006 Aug; 19(5):593-8. PubMed ID: 16645958
[TBL] [Abstract][Full Text] [Related]
6. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
Jensen LR; Huuse EM; Bathen TF; Goa PE; Bofin AM; Pedersen TB; Lundgren S; Gribbestad IS
NMR Biomed; 2010 Jan; 23(1):56-65. PubMed ID: 19650073
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
8. In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts.
Esmaeili M; Moestue SA; Hamans BC; Veltien A; Kristian A; Engebråten O; Maelandsmo GM; Gribbestad IS; Bathen TF; Heerschap A
J Magn Reson Imaging; 2015 Mar; 41(3):601-9. PubMed ID: 24532410
[TBL] [Abstract][Full Text] [Related]
9. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts.
Morse DL; Raghunand N; Sadarangani P; Murthi S; Job C; Day S; Howison C; Gillies RJ
Magn Reson Med; 2007 Aug; 58(2):270-80. PubMed ID: 17654590
[TBL] [Abstract][Full Text] [Related]
10. Investigation of metabolite changes in the transition from pre-invasive to invasive cervical cancer measured using (1)H and (31)P magic angle spinning MRS of intact tissue.
De Silva SS; Payne GS; Thomas V; Carter PG; Ind TE; deSouza NM
NMR Biomed; 2009 Feb; 22(2):191-8. PubMed ID: 18833545
[TBL] [Abstract][Full Text] [Related]
11. Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.
Esmaeili M; Bathen TF; Engebråten O; Mælandsmo GM; Gribbestad IS; Moestue SA
Magn Reson Med; 2014 Jun; 71(6):1973-81. PubMed ID: 23878023
[TBL] [Abstract][Full Text] [Related]
12. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.
Su MY; Baik HM; Yu HJ; Chen JH; Mehta RS; Nalcioglu O
Technol Cancer Res Treat; 2006 Aug; 5(4):401-10. PubMed ID: 16866570
[TBL] [Abstract][Full Text] [Related]
13. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI).
Danishad KK; Sharma U; Sah RG; Seenu V; Parshad R; Jagannathan NR
NMR Biomed; 2010 Apr; 23(3):233-41. PubMed ID: 20175134
[TBL] [Abstract][Full Text] [Related]
14. Current dilemmas and future perspectives for breast cancer screening with a focus on optimization of magnetic resonance spectroscopic imaging by advances in signal processing.
Belkic K
Isr Med Assoc J; 2004 Oct; 6(10):610-8. PubMed ID: 15473589
[TBL] [Abstract][Full Text] [Related]
15. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy.
Sitter B; Bathen TF; Singstad TE; Fjøsne HE; Lundgren S; Halgunset J; Gribbestad IS
NMR Biomed; 2010 May; 23(4):424-31. PubMed ID: 20101607
[TBL] [Abstract][Full Text] [Related]
16. [1H magnetic resonance spectroscopy of the prostate].
Mueller-Lisse UG; Scherr M
Radiologe; 2003 Jun; 43(6):481-8. PubMed ID: 12827263
[TBL] [Abstract][Full Text] [Related]
17. Quantitative 31P magnetic resonance spectroscopy of the human breast at 7 T.
Wijnen JP; van der Kemp WJ; Luttje MP; Korteweg MA; Luijten PR; Klomp DW
Magn Reson Med; 2012 Aug; 68(2):339-48. PubMed ID: 22213214
[TBL] [Abstract][Full Text] [Related]
18. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.
Sitter B; Lundgren S; Bathen TF; Halgunset J; Fjosne HE; Gribbestad IS
NMR Biomed; 2006 Feb; 19(1):30-40. PubMed ID: 16229059
[TBL] [Abstract][Full Text] [Related]
19. Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study.
Sterin M; Cohen JS; Mardor Y; Berman E; Ringel I
Cancer Res; 2001 Oct; 61(20):7536-43. PubMed ID: 11606391
[TBL] [Abstract][Full Text] [Related]
20. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration.
Mahon MM; Williams AD; Soutter WP; Cox IJ; McIndoe GA; Coutts GA; Dina R; deSouza NM
NMR Biomed; 2004 Feb; 17(1):1-9. PubMed ID: 15011245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
